Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Today, Benzinga's options scanner spotted 33 options trades for Pfizer. This is not a typical pattern. The sentiment among these major traders is split, with 66% bullish and 33% bearish. Among all the ...

The company posted adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the consensus of 47 cents. The U.S.

Highlights,Welch Group LLC reduced its position in Pfizer,(NYSE:PFE),by over 35% in the fourth quarter.,Institutional ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...

Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...

US pharmaceutical giant Pfizer Inc returned to profit in the fourth quarter from a loss in the same period of the previous ...